

## Fas Ligand Protein, Rat (P.pastoris, His)

<b>Cat. No.:</b>	HY-P74156
<b>Synonyms:</b>	Tumor necrosis factor ligand superfamily member 6; APTL; CD95-L; Fas ligand; FasL; CD178; TNFSF6
<b>Species:</b>	Rat
<b>Source:</b>	P. pastoris
<b>Accession:</b>	P36940 (L104-L278)
<b>Gene ID:</b>	25385
<b>Molecular Weight:</b>	Approximately 21.3 kDa

### PROPERTIES

<b>Appearance</b>	Lyophilized powder.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
<b>Endotoxin Level</b>	<1 EU/µg, determined by LAL method.
<b>Reconstitution</b>	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O.
<b>Storage &amp; Stability</b>	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
<b>Shipping</b>	Room temperature in continental US; may vary elsewhere.

### DESCRIPTION

<b>Background</b>	<p>Fas Ligand (FasL; FASLG; CD95L), is a ligand for TNFRSF6/FAS belonging to the tumor necrosis factor (TNF). FasL is a type II transmembrane protein, triggering apoptosis of lymphocytes<sup>[1]</sup>.</p> <p>FasL is expressed on a variety of cell types, including T cells, natural killer (NK) cells, monocytes, neutrophils, breast epithelial cells, and vascular endothelial cells<sup>[3]</sup>.</p> <p>FasL exerts different biological activity by cleaved into 4 isoforms including membrane form, soluble form, ADAM10-processed FasL form (APL) and SPPL2A-processed FasL form (SPA). Among them, the membrane-bound form and a soluble form generated by proteolytic action of matrix metalloproteinases (MMP)<sup>[3]</sup>.</p> <p>FasL or soluble FasL binding to Fas results in receptor aggregation and in the interaction of a protein called Fas-associated death domain with the Fas cytoplasmic tail. The interaction triggers a cascade of intracellular events, including the activation of the IL-1-converting enzyme-like cysteine protease (caspase 8), that ultimately leads to nucleoprotein cleavage, DNA fragmentation, and cell apoptosis<sup>[5]</sup>.</p> <p>Fas-Fas Ligand system in rat is one of the main mediators of apoptosis in experimental autoimmune orchitis (EAO), involves in germ cell (GC) death induction<sup>[4]</sup>.</p> <p>The loss of function due to mutations in murine FasL, murine Fas, human Fas, or human FasL leads to lymphoproliferation, lymphadenopathy, and autoimmune diseases<sup>[1][3]</sup>.</p>
-------------------	--

---

Meanwhile, defective activation-induced cell death (AICD) results in spontaneous mutation of Fas and FasL genes in mice with lupus-like autoimmune disease<sup>[3]</sup>.

Human Fas Ligand also involves in Jurkat cell apoptosis and binds TNFRSF6B/DcR3 to block apoptosis, which is a decoy receptor of apoptosis termination<sup>[3]</sup>.

FasL is widely found in different animals, while the sequence in Mouse is highly similar to Rat (91.37%), but very different from Human with similarity of 78.06%.

FasL is widely found in different animals, while the sequence in Rat is highly similar to Mouse (91.37%), but very different from Human with similarity of 77.26%.

---

## REFERENCES

- [1]. Schneider P, et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. *J Biol Chem.* 1997 Jul 25;272(30):18827-33.
  - [2]. Liu W, et al. Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3. *Structure.* 2016 Nov 1;24(11):2016-2023.
  - [3]. Martínez-Lorenzo MJ, et al. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. *Immunology.* 1996 Dec;89(4):511-7.
  - [4]. Jacobo PV, et al. Involvement of soluble Fas Ligand in germ cell apoptosis in testis of rats undergoing autoimmune orchitis. *Cytokine.* 2012 Nov;60(2):385-92.
  - [5]. Puppo F, et al. Fas, Fas ligand, and transfusion immunomodulation. *Transfusion.* 2001 Mar;41(3):416-8.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA